Immunological effects of sublingual immunotherapy: Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4

Stefania Piconi, Daria Trabattoni, Veronica Rainone, Linda Borgonovo, Simone Passerini, Giuliano Rizzardini, Franco Frati, Enrico Iemoli, Mario Clerici

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunotherapy with an improved safety profile; to clarify the immune mechanisms elicited by this therapy, we analyzed the clinical and immunologic effects of SLIT in patients with a clinical history of ragweed sensitization. To analyze possible difference among immunotherapeutic protocols, we also compared patients receiving preseasonal, seasonal, or prolonged sublingual therapy (≥3 y); patients receiving symptomatic therapy alone were enrolled as well in the study. Clinical and immunological parameters were measured twice in and out of the pollination period. Clinical benefits, as measured by the visual analog scale for symptoms and for use of drugs, were evident in all three groups of individuals receiving immunotherapy, but were significantly better in patients undergoing prolonged SLIT. Immunologically, SLIT resulted in increased IL-10 production, programmed cell death ligand 1 expression, and concentration of allergen-specific IgG4, as well as in the reduction of CD80 and CD86 expression and IL-4 production. SLIT, thus, is associated with modulation of programmed cell death ligand 1 expression and IL-10 synthesis and favors the production of allergen-specific IgG4. These effects are evident from the first pollen season, independently from therapeutic regimen (preseasonal or seasonal) even if a prolonged treatment is necessary to obtain full clinical efficacy. A more detailed understanding of the interaction of allergen and APCs within the oral mucosa will allow improved targeting of allergy vaccine.

Original languageEnglish
Pages (from-to)7723-7730
Number of pages8
JournalJournal of Immunology
Volume185
Issue number12
DOIs
Publication statusPublished - Dec 15 2010

Fingerprint

Sublingual Immunotherapy
Interleukin-10
Cell Death
Immunoglobulin G
Ligands
Allergens
Immunologic Desensitization
Ambrosia
Therapeutics
Pollination
Mouth Mucosa
Pollen
Visual Analog Scale
Interleukin-4
Immunotherapy
Hypersensitivity
Vaccines
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Immunological effects of sublingual immunotherapy : Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. / Piconi, Stefania; Trabattoni, Daria; Rainone, Veronica; Borgonovo, Linda; Passerini, Simone; Rizzardini, Giuliano; Frati, Franco; Iemoli, Enrico; Clerici, Mario.

In: Journal of Immunology, Vol. 185, No. 12, 15.12.2010, p. 7723-7730.

Research output: Contribution to journalArticle

Piconi, Stefania ; Trabattoni, Daria ; Rainone, Veronica ; Borgonovo, Linda ; Passerini, Simone ; Rizzardini, Giuliano ; Frati, Franco ; Iemoli, Enrico ; Clerici, Mario. / Immunological effects of sublingual immunotherapy : Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. In: Journal of Immunology. 2010 ; Vol. 185, No. 12. pp. 7723-7730.
@article{45baea21d60340daa3ee9d6131eaed38,
title = "Immunological effects of sublingual immunotherapy: Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4",
abstract = "Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunotherapy with an improved safety profile; to clarify the immune mechanisms elicited by this therapy, we analyzed the clinical and immunologic effects of SLIT in patients with a clinical history of ragweed sensitization. To analyze possible difference among immunotherapeutic protocols, we also compared patients receiving preseasonal, seasonal, or prolonged sublingual therapy (≥3 y); patients receiving symptomatic therapy alone were enrolled as well in the study. Clinical and immunological parameters were measured twice in and out of the pollination period. Clinical benefits, as measured by the visual analog scale for symptoms and for use of drugs, were evident in all three groups of individuals receiving immunotherapy, but were significantly better in patients undergoing prolonged SLIT. Immunologically, SLIT resulted in increased IL-10 production, programmed cell death ligand 1 expression, and concentration of allergen-specific IgG4, as well as in the reduction of CD80 and CD86 expression and IL-4 production. SLIT, thus, is associated with modulation of programmed cell death ligand 1 expression and IL-10 synthesis and favors the production of allergen-specific IgG4. These effects are evident from the first pollen season, independently from therapeutic regimen (preseasonal or seasonal) even if a prolonged treatment is necessary to obtain full clinical efficacy. A more detailed understanding of the interaction of allergen and APCs within the oral mucosa will allow improved targeting of allergy vaccine.",
author = "Stefania Piconi and Daria Trabattoni and Veronica Rainone and Linda Borgonovo and Simone Passerini and Giuliano Rizzardini and Franco Frati and Enrico Iemoli and Mario Clerici",
year = "2010",
month = "12",
day = "15",
doi = "10.4049/jimmunol.1002465",
language = "English",
volume = "185",
pages = "7723--7730",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Immunological effects of sublingual immunotherapy

T2 - Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4

AU - Piconi, Stefania

AU - Trabattoni, Daria

AU - Rainone, Veronica

AU - Borgonovo, Linda

AU - Passerini, Simone

AU - Rizzardini, Giuliano

AU - Frati, Franco

AU - Iemoli, Enrico

AU - Clerici, Mario

PY - 2010/12/15

Y1 - 2010/12/15

N2 - Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunotherapy with an improved safety profile; to clarify the immune mechanisms elicited by this therapy, we analyzed the clinical and immunologic effects of SLIT in patients with a clinical history of ragweed sensitization. To analyze possible difference among immunotherapeutic protocols, we also compared patients receiving preseasonal, seasonal, or prolonged sublingual therapy (≥3 y); patients receiving symptomatic therapy alone were enrolled as well in the study. Clinical and immunological parameters were measured twice in and out of the pollination period. Clinical benefits, as measured by the visual analog scale for symptoms and for use of drugs, were evident in all three groups of individuals receiving immunotherapy, but were significantly better in patients undergoing prolonged SLIT. Immunologically, SLIT resulted in increased IL-10 production, programmed cell death ligand 1 expression, and concentration of allergen-specific IgG4, as well as in the reduction of CD80 and CD86 expression and IL-4 production. SLIT, thus, is associated with modulation of programmed cell death ligand 1 expression and IL-10 synthesis and favors the production of allergen-specific IgG4. These effects are evident from the first pollen season, independently from therapeutic regimen (preseasonal or seasonal) even if a prolonged treatment is necessary to obtain full clinical efficacy. A more detailed understanding of the interaction of allergen and APCs within the oral mucosa will allow improved targeting of allergy vaccine.

AB - Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunotherapy with an improved safety profile; to clarify the immune mechanisms elicited by this therapy, we analyzed the clinical and immunologic effects of SLIT in patients with a clinical history of ragweed sensitization. To analyze possible difference among immunotherapeutic protocols, we also compared patients receiving preseasonal, seasonal, or prolonged sublingual therapy (≥3 y); patients receiving symptomatic therapy alone were enrolled as well in the study. Clinical and immunological parameters were measured twice in and out of the pollination period. Clinical benefits, as measured by the visual analog scale for symptoms and for use of drugs, were evident in all three groups of individuals receiving immunotherapy, but were significantly better in patients undergoing prolonged SLIT. Immunologically, SLIT resulted in increased IL-10 production, programmed cell death ligand 1 expression, and concentration of allergen-specific IgG4, as well as in the reduction of CD80 and CD86 expression and IL-4 production. SLIT, thus, is associated with modulation of programmed cell death ligand 1 expression and IL-10 synthesis and favors the production of allergen-specific IgG4. These effects are evident from the first pollen season, independently from therapeutic regimen (preseasonal or seasonal) even if a prolonged treatment is necessary to obtain full clinical efficacy. A more detailed understanding of the interaction of allergen and APCs within the oral mucosa will allow improved targeting of allergy vaccine.

UR - http://www.scopus.com/inward/record.url?scp=78650630382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650630382&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1002465

DO - 10.4049/jimmunol.1002465

M3 - Article

C2 - 21076061

AN - SCOPUS:78650630382

VL - 185

SP - 7723

EP - 7730

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -